Thyroid Hormone Effects on Mesenchymal Stem Cell Biology in the Tumour Microenvironment

Abstract

Non-classical thyroid hormone signalling via cell surface receptor integrin αvβ3, expressed on most cancer cells and proliferating endothelial cells, has been shown to drive tumour cell proliferation and survival, as well as angiogenesis. Tumours develop within a complex microenvironment that is composed of many different cell types, including mesenchymal stem cells. These multipotent progenitor cells actively home to growing tumours where they differentiate into cancer-associated fibroblast-like cells and blood vessel-stabilising pericytes and thus support the tumour’s fibrovascular network. Integrin αvβ3 expression on mesenchymal stem cells makes them susceptible to thyroid hormone stimulation. Indeed, our studies demonstrated – for the first time – that thyroid hormones stimulate the differentiation of mesenchymal stem cells towards a carcinoma-associated fibroblast-/pericyte-like and hypoxia-responsive, pro-angiogenic phenotype, characterised by the secretion of numerous paracrine pro-angiogenic factors, in addition to driving their migration, invasion, and recruitment to the tumour microenvironment in an experimental hepatocellular carcinoma model. The deaminated thyroid hormone metabolite tetrac, a specific inhibitor of thyroid hormone action at the integrin site, reverses these effects. The modulation of mesenchymal stem cell signalling and recruitment by thyroid hormones via integrin αvβ3 adds a further layer to the multifaceted effects of thyroid hormones on tumour progression, with important implications for the management of cancer patients and suggests a novel mechanism for the anti-tumour activity of tetrac.

Key words

integrin αvβ3 - T3 - T4 - tetrac - angiogenesis - cancer

• References

• 1 Bergh JJ, Lin HY, Lansing L. et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005; 146: 2864-2871
• 2 Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nature Reviews Endocrinology 2016; 12: 111-121
• 3 Schmohl KA, Nelson PJ, Spitzweg C. Tetrac as an anti-angiogenic agent in cancer. Endocr Relat Cancer 2019; 26: R287-r304
• 4 Hercbergs A, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes 2010; 17: 432-436
• 5 Moeller LC, Führer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer 2013; 20: R19-R29
• 6 Khan SR, Chaker L, Ruiter R. et al. Thyroid function and cancer risk: The Rotterdam Study. The Journal of Clinical Endocrinology and Metabolism 2016; 101: 5030-5036
• 7 Krashin E, Piekielko-Witkowska A, Ellis M. et al. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne) 2019; 10: 59
• 8 Davis PJ, Davis FB, Lin HY. et al. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 2009; 297: E1238-E1246
• 9 Schmohl KA, Müller AM, Wechselberger A. et al. Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3. Endocr Relat Cancer 2015; 22: 941-952
• 10 Davis PJ, Leonard JL, Lin HY. et al. Molecular basis of nongenomic actions of thyroid hormone. Vitam Horm 2018; 106: 67-96
• 11 Lin HY, Sun M, Tang HY. et al. L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009; 296: C980-C991
• 12 Davis PJ, Lin HY, Hercbergs AA. et al. How thyroid hormone works depends upon cell type, receptor type, and hormone analogue: implications in cancer growth. Discov Med 2019; 27: 111-117
• 13 Dwyer RM, Kerin MJ. Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?. Hum Gene Ther 2010; 21: 1506-1512
• 14 Chandler C, Liu T, Buckanovich R. et al. The double edge sword of fibrosis in cancer. Transl Res 2019; 209: 55-67
• 15 Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res 2015; 3: 1-11
• 16 Hagenhoff A, Bruns CJ, Zhao Y. et al. Harnessing mesenchymal stem cell homing as an anticancer therapy. Expert Opin Biol Ther 2016; 16: 1079-1092
• 17 Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659
• 18 Schug C, Kitzberger C, Sievert W. et al. Radiation-induced Amplification of TGFB1-induced Mesenchymal Stem Cell-mediated Sodium Iodide Symporter (NIS) Gene 131 I Therapy. Clin Cancer Res 2019; 25: 5997-6008
• 19 Schug C, Sievert W, Urnauer S. et al. External beam radiation therapy enhances mesenchymal stem cell-mediated sodium-iodide symporter gene delivery. Hum Gene Ther 2018; 29: 1287-1300
• 20 Vitale I, Manic G, Galassi C. et al. Stress responses in stromal cells and tumor homeostasis. Pharmacol Ther 2019; 200: 55-68
• 21 Spaeth EL, Dembinski JL, Sasser AK. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: e4992
• 22 Wels J, Kaplan RN, Rafii S. et al. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008; 22: 559-574
• 23 Gieniec KA, Butler LM, Worthley DL. et al. Cancer-associated fibroblasts-heroes or villains?. Br J Cancer 2019; 121: 293-302
• 24 Bronckaers A, Hilkens P, Martens W. et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacol Ther 2014; 143: 181-196
• 25 Barcellos-de-Souza P, Gori V, Bambi F. et al. Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta 2013; 1836: 321-335
• 26 Schmohl KA, Mueller AM, Dohmann M et al. Integrin αvβ3-mediated effects of thyroid hormones on mesenchymal stem cells in tumour angiogenesis. Thyroid 2019 (in press)
• 27 Lin HY, Su YF, Hsieh MT. et al. Nuclear monomeric integrin αv in cancer cells is a coactivator regulated by thyroid hormone. FASEB Journal 2013; 27: 3209-3216
• 28 Lin HY, Cody V, Davis FB. et al. Identification and functions of the plasma membrane receptor for thyroid hormone analogues. Discov Med 2011; 11: 337-347
• 29 Davis PJ, Glinsky GV, Lin HY. et al. Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac. Front Endocrinol 2015; 5: 240
• 30 Davis PJ, Sudha T, Lin HY. et al. Thyroid Hormone, Hormone Analogs, and Angiogenesis. Compr Physiol 2015; 6: 353-362
• 31 Moeller LC, Dumitrescu AM, Refetoff S. Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1alpha and glycolytic genes. Mol Endocrinol 2005; 19: 2955-2963
• 32 Moeller LC, Cao X, Dumitrescu AM. et al. Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor beta through the phosphatidylinositol 3-kinase pathway. Nucl Recept Signal 2006; 4: e020
• 33 Luidens MK, Mousa SA, Davis FB. et al. Thyroid hormone and angiogenesis. Vascul Pharmacol 2010; 52: 142-145
• 34 Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 2002; 57: 559-574
• 35 Knoop K, Kolokythas M, Klutz K. et al. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther 2011; 19: 1704-1713
• 36 Knoop K, Schwenk N, Dolp P. et al. Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. Hum Gene Ther 2013; 24: 306-316
• 37 Knoop K, Schwenk N, Schmohl K. et al. Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene. J Nucl Med 2015; 56: 600-606
• 38 Müller AM, Schmohl KA, Knoop K. et al. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Oncotarget 2016; 7: 54795-54810
• 39 Schug C, Gupta A, Urnauer S. et al. A novel approach for image-guided ¹³¹i therapy of pancreatic ductal adenocarcinoma using mesenchymal stem cell-mediated nis gene delivery. Mol Cancer Res 2019; 17: 310-320
• 40 Schug C, Urnauer S, Jaeckel C. et al. TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer. Endocr Relat Cancer 2019; 26: 89-101
• 41 Balzan S, Del Carratore R, Nardulli C. et al. The stimulative effect of T3 and T4 on human myocardial endothelial cell proliferation, migration and angiogenesis. J Clin Exp Cardiolog 2013; 4: 280-286
• 42 Mousa SA, Lin HY, Tang HY. et al. Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis 2014; 17: 463-469
• 43 Liu X, Zheng N, Shi YN. et al. Thyroid hormone induced angiogenesis through the integrin αvβ3/protein kinase D/histone deacetylase 5 signaling pathway. J Mol Endocrinol 2014; 52: 245-254
• 44 Mousa SA, Davis FB, Mohamed S. et al. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 2006; 25: 407-413
• 45 Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005; 7: 452-464
• 46 Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193-215
• 47 Schmohl KA, Müller AM, Schwenk N. et al. Establishment of an effective radioiodide thyroid ablation protocol in mice. Eur Thyroid J 2015; 4: 74-80
• 48 De Vito P, Balducci V, Leone S. et al. Nongenomic effects of thyroid hormones on the immune system cells: New targets, old players. Steroids 2012; 77: 988-995
• 49 Cohen K, Flint N, Shalev S. et al. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells. Oncotarget 2014; 5: 6312-6322
• 50 Spaeth E, Klopp A, Dembinski J. et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008; 15: 730-738
• 51 Davis PJ, Davis FB, Mousa SA. et al. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 2011; 51: 99-115
• 52 Hercbergs A, Davis FB, Lin HY. et al. Integrin-mediated actions of thyroid hormone analogues on tumor cell chemosensitivity, integrin-growth factor receptor crosstalk and inflammatory gene expression. Cancer Clin Oncol 2012; 1: 32-40
• 53 Zischek C, Niess H, Ischenko I. et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009; 250: 747-753
• 54 Niess H, Bao Q, Conrad C. et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg 2011; 254: 767-775
• 55 Conrad C, Husemann Y, Niess H. et al. Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis. Ann Surg 2011; 253: 566-571